Persistent URL of this record https://hdl.handle.net/1887/100328
In Collections
This item can be found in the following collections:
![Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study](https://scholarlypublications.universiteitleiden.nl/sites/all/themes/scholarly/img/closed_access.png)
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study
- All authors
- Smolen, J.S.; Weinblatt, M.E.; Heijde, D. van der; Rigby, W.F.C.; Vollenhoven, R. van; Bingham, C.O.; Veenhuizen, M.; Gill, A.; Zhao, F.Y.; Komocsar, W.J.; Berclaz, P.Y.; Ortmann, R.; Lee, C.
- Date
- 2015-08-31
- Journal
- Annals of the Rheumatic Diseases
- Volume
- 74
- Issue
- 8
- Pages
- 1567 - 1570